Neuro-Oncology
Paraneoplastic syndromes
Oct. 15, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Acute disseminated encephalomyelitis (ADEM) …
- Updated 04.11.2024
- Released 05.08.1995
- Expires For CME 04.11.2027
Acute disseminated encephalomyelitis
Introduction
Overview
Approximately 25% of all children with an acute inflammatory demyelinating attack in the central nervous system will meet consensus criteria for a diagnosis of acute disseminated encephalomyelitis. Acute disseminated encephalomyelitis is clinically defined by polyfocal neurologic deficits and encephalopathy and is radiologically characterized by multifocal areas of increased signal in both white and gray matter of the brain and spinal cord visible on T2/FLAIR-weighted magnetization resonance images. Acute disseminated encephalomyelitis is primarily a pediatric disorder, though adults may also be affected. Though the etiologic mechanisms have not been fully elucidated, acute disseminated encephalomyelitis is thought to be an immune-mediated process and is often precipitated by preceding viral infection. Acute disseminated encephalomyelitis is typically a monophasic illness, but a multiphasic form, and relapses involving the optic nerves can occur, often in the context of myelin oligodendrocyte glycoprotein (MOG) antibody seropositivity. There are no laboratory features diagnostic of acute disseminated encephalomyelitis, though about 50% of patients are MOG antibody seropositive at initial presentation. The authors discuss clinical and imaging features, etiology, differential diagnosis, and management of acute disseminated encephalomyelitis. Pathogenesis is also discussed, with updates focusing on the implications of myelin oligodendrocyte glycoprotein antibody seropositivity.
Key points
|
• Acute disseminated encephalomyelitis is an inflammatory demyelinating disorder predominantly affecting white and gray matter in the brain and spinal cord. | |
|
• Acute disseminated encephalomyelitis is more common in children than in adults. | |
|
• Acute disseminated encephalomyelitis is thought to be an immune-mediated process that often follows viral illness. | |
|
• Acute disseminated encephalomyelitis is clinically defined by encephalopathy and polyfocal neurologic deficits. | |
|
• Approximately 50% of children with acute disseminated encephalomyelitis have serological antibodies against myelin oligodendrocyte glycoprotein at the time of initial presentation. | |
|
• Acute treatment with corticosteroids is usually effective, and the course is typically monophasic. |
Historical note and terminology
Delayed neurologic complications after infections have been described since the 1700s. In the 1920s, pathologic differences between acute encephalitis and postinfectious encephalomyelitis were described, as were similarities between postinfectious and postvaccination (eg, rabies) encephalomyelitis. The first animal model of encephalomyelitis was produced in 1935 by Rivers and Schwentker by injecting monkeys with rabbit brain or spinal cord tissue; studies of this model suggested that delayed neurologic complications manifesting as encephalomyelitis following infections or vaccinations could result from sensitization of the immune system to proteins expressed by viruses (molecular mimicry) or by vaccines that contained proteins from neural tissue.
Early reports of postinfectious encephalomyelitis came from pediatric populations, following exanthematous infections. The term "acute disseminated encephalomyelitis" was introduced to describe any immune-mediated encephalomyelitis that resulted from infection, allergies, or vaccinations (64).
Historically, there has been inconsistent use and application of the term “acute disseminated encephalomyelitis” due to a lack of clear diagnostic criteria. As a result, the International Pediatric Multiple Sclerosis Study Group (IPMSSG) created an operational definition for acute disseminated encephalomyelitis in 2007, which was then updated in 2013. By definition, acute disseminated encephalomyelitis is an initial acute inflammatory event characterized by encephalopathy with polyfocal neurologic deficits occurring over a maximum period of clinical evolution of 3 months. MRI features include multifocal, large, and asymmetric areas of increased T2/FLAIR signal affecting the white and gray matter of the CNS (33; 34).
The requirement for encephalopathy in the definition of acute disseminated encephalomyelitis is considered essential by the consensus panel to avoid diagnosing every child with polyfocal MRI lesions with acute disseminated encephalomyelitis.
Table 1. IPMSSG Definition for Monophasic Acute Disseminated Encephalomyelitis
|
1. A first multifocal, clinical CNS event of presumed inflammatory demyelinating cause. | ||
|
2. Encephalopathy that cannot be explained by fever. | ||
|
3. Abnormal brain MRI: | ||
|
a. Diffuse, poorly demarcated, large (larger than 1 to 2 cm) lesions involving predominantly the cerebral white matter. | ||
|
b. T1 hypointense lesions in the white matter are rare. | ||
|
c. Deep gray matter abnormalities (eg, thalamus or basal ganglia) can be present. | ||
|
4. No new clinical and MRI findings after three months of symptom onset. | ||
|
5. Reasonable exclusion of alternative causes. | ||
The International Pediatric Multiple Sclerosis Study Group redefined multiphasic disseminated encephalomyelitis in their 2013 consensus paper. Multiphasic disseminated encephalomyelitis is now defined as repeated episodes of demyelination that are separated by at least 3 months, with each episode meeting the definition of acute disseminated encephalomyelitis, and no evidence of either clinically silent lesion accrual on MRI or any other demyelinating attacks (attacks not meeting criteria for acute disseminated encephalomyelitis) (34). Children with initial event meeting criteria for acute disseminated encephalomyelitis, but who then experience repeated attacks that do not meet criteria for acute disseminated encephalomyelitis, should be evaluated for other disorders, in particular MOG antibody-associated disease (MOGAD).
Clinical manifestations
Presentation and course
Initial symptoms of acute disseminated encephalomyelitis may occur spontaneously without antecedent illness or, more typically, begin between 2 days and 4 weeks after a febrile illness of presumed viral etiology (01). The actual microbial illness is rarely determined. Clinical presentation includes encephalopathy (which may manifest as behavioral change, profound irritability, or altered consciousness) that cannot be explained by fever and polyfocal neurologic deficits (34; 61). Systemic symptoms such as fever, headache, and fatigue often precede the development of neurologic deficits. Once neurologic symptoms begin, the course is rapidly progressive, and patients typically develop maximal symptoms within 3 to 5 days (61).
Neurologic signs and symptoms vary in acute disseminated encephalomyelitis and are determined by the location of lesions in the CNS. In a prospective series of 84 patients, the most common presenting features of acute disseminated encephalomyelitis included long tract signs (85%), acute hemiparesis (76%), and cerebellar ataxia (50%), in addition to encephalopathy (59). Less common presenting features included cranial nerve palsies, spinal cord involvement, aphasia, seizures, and visual dysfunction.
The severity of symptoms varies in acute disseminated encephalomyelitis as some children may present with mild somnolence and subtle neurologic dysfunction, whereas others rapidly develop obtundation and respiratory depression necessitating intensive care. Respiratory failure secondary to brainstem involvement or severely impaired consciousness has been reported in 11% to 16% of cases (60). In fulminant cases, cerebral edema and increased intracranial pressure can occur and result in death or severe neurologic dysfunction if not intervened on quickly.
Prognosis and complications
Although the majority of patients with acute disseminated encephalomyelitis completely recover, the acute phase can be severe and life-threatening, and minor residual deficits have been reported in 20% to 30% of children (55; 61). Of these residual deficits, the most frequently reported include mild motor deficits, visual problems, and seizures (59). Children with a history of acute disseminated encephalomyelitis have also been shown to report increased fatigue and have decreased exercise capacity when compared to healthy peers (63).
The average time to full recovery ranges from 1 to 6 months, though patients often experience immediate improvement of symptoms after beginning treatment with corticosteroids. In a cohort of 24 children with acute disseminated encephalomyelitis, time until initial improvement was 7.0±4.5 days, and time until full recovery was 27±34 days (51). Sixty-five percent of this cohort improved within 3 days of high dose methylprednisolone administration (51). The mortality of acute disseminated encephalomyelitis had previously been reported to be as high as 20% (47). However, in the era of modern treatment agents for inflammation and elevated intracranial pressure, this figure has been markedly reduced. One group aimed to identify clinical and radiologic risk factors that might predict poor functional outcomes by retrospectively reviewing patients with ADEM with moderate to severe disease severity and found that a higher percentage of those who presented with dystonia and myoclonus had poor recovery as did those with more cerebellar lesions (15). Of note, only a few of the patients in this cohort were tested for MOG antibodies.
Cognitive and learning deficits have also been reported as long-term consequences of acute disseminated encephalomyelitis. Subtle deficits in executive function, attention, and behavior have been reported in children who have otherwise completely recovered from acute disseminated encephalomyelitis (35; 57). These deficits have been noted to be more prominent in children who were younger than 5 years of age at the time of their diagnosis (28). Attention may improve over time as patients tested further from the diagnosis tend to have better neurocognitive test scores (57).
It has been shown that although the clinical characteristics and presenting features of adult-onset acute disseminated encephalomyelitis can be similar to pediatric-onset disease, the outcome and disease course can be more severe. In fact, in a retrospective review looking at prognosis and disease course in adults and children with acute disseminated encephalomyelitis, it was found that adults were more likely to require longer hospitalization and intensive care admission. Outcome in adult-onset disease was also worse as fewer adults had complete motor recovery (32).
Acute disseminated encephalomyelitis is typically a monophasic disorder. However, some children with a first demyelinating attack meeting criteria for acute disseminated encephalomyelitis will ultimately be diagnosed with multiple sclerosis. The reported percentage of patients with an ultimate diagnosis of multiple sclerosis varies in different cohorts based on the inclusion criteria and definition of acute disseminated encephalomyelitis used. For instance, although one prospective study reported that 18% of their acute disseminated encephalomyelitis cohort eventually had a confirmed diagnosis of multiple sclerosis, a prospective study of 302 children with acute demyelinating syndromes and strict definitions for acute disseminated encephalomyelitis reported that only 4 of 77 patients (5%) initially diagnosed with acute disseminated encephalomyelitis were subsequently diagnosed with multiple sclerosis (46; 06).
Though multiple sclerosis and neuromyelitis optica spectrum disorder must be considered in a patient with relapsing demyelination following an initial episode of acute disseminated encephalomyelitis, other disorders such as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) should also be considered (21; 56). Proposed diagnostic criteria for MOGAD have been published in an effort to improve identification of individuals with this disorder (Table 2) (07).
Table 2. Diagnostic Criteria for MOGAD (A, B, and C are required)
|
A) Core clinical demyelinating event |
• Optic neuritis | |
|
B) Positive MOG-antibody test |
• Cell-based assay serum |
• No additional supporting features required |
|
• Low positive |
• AQP4-IgG seronegativity AND ≥1 supporting clinical or MRI feature (Table 3) | |
|
C) Exclusion of alternative diagnosis including multiple sclerosis | ||
Table 3. Supporting Clinical or MRI Features for MOGAD Diagnosis
|
Optic neuritis |
• Bilateral simultaneous clinical involvement |
|
Myelitis |
• Longitudinally extensive myelitis |
|
Brain, brainstem, or cerebellar syndrome |
• Multiple ill-defined T2 hyperintense supra and often intratentorial white matter lesions |
Although patients with acute disseminated encephalomyelitis often make a full clinical recovery, one study has shown that these children (along with children with multiple sclerosis and clinically isolated syndromes) have impaired cerebellar growth and cerebellar volume reduction (68). This has not yet been correlated with disability or persistent clinical symptomatology, but further studies are needed to better understand the clinical implication of this finding (68).
It has also been shown that children with acquired monophasic demyelination, especially those with acute disseminated encephalomyelitis, demonstrated reduced age-expected brain growth, which is thought to be primarily driven by reduced white matter growth (05). The clinical implications of this are still unknown. Additionally, when looking at serial measurements of normal appearing white matter using diffusion tensor imaging in children with acquired demyelinating syndromes, there was a decline from age-expected values not only in those with multiple sclerosis, but also in those with acute disseminated encephalomyelitis (37). A study has also corroborated that patients with acute disseminated encephalomyelitis showed reduced brain volume at baseline compared with matched controls, in addition to a reduction in age-expected brain growth over time (10). Volume loss was more pronounced in patients with acute disseminated encephalomyelitis who were seronegative for MOG antibodies compared to those who were seropositive (10).
Clinical vignette
A developmentally normal 4-year-old boy was admitted with depressed consciousness and inability to walk or sit up independently. His lethargy and truncal instability had progressed over the preceding 4 days. Of note, he had a diarrheal illness 1 week prior to his presentation and had developed low-grade fever 4 days prior to his admission. His vital signs and general medical exam on admission were normal. His neurologic exam was notable for a somnolent mental status, dysarthria, and severe truncal and appendicular ataxia. Initial labs, including a complete blood count and electrolyte panel, were normal. Cerebrospinal fluid (CSF) studies showed 48 white blood cells per mm3 (predominantly lymphocytes), few red blood cells, normal glucose, and a mildly elevated protein. Oligoclonal bands were negative. Viral PCR studies and a bacterial culture from the CSF were negative. MRI of the brain revealed multifocal T2-hyperintense lesions involving both cerebral hemispheres, the pons, the middle cerebellar peduncles, and the cerebellum, with some lesions showing patchy enhancement with gadolinium. Serum MOG antibody was positive.
Intravenous methylprednisolone was started after the MRI was completed. Within 24 hours of starting corticosteroids, the patient become more alert and was able to sit independently. Over the following 2 days, the patient’s clinical condition improved rapidly; his dysarthria resolved, and he was able to walk with support. The patient was discharged home with an oral prednisone taper. Two weeks later, the patient was asymptomatic and had returned to baseline. A brain MRI was repeated 6 months after discharge and showed complete resolution of his initial lesions and no new lesions.
Biological basis
Etiology and pathogenesis
Nonspecific upper respiratory tract infections have been reported to be the most common illnesses preceding acute disseminated encephalomyelitis (30; 49; 59). Less common precedent infections include varicella, herpes simplex virus encephalitis, mycoplasma, enterovirus, Zika virus (50), Chikungunya (58), Saint Louis encephalitis virus (53), and SARS-CoV-2 (44; 70).
The level of evidence for a direct association between vaccines and acute disseminated encephalomyelitis remains anecdotal. In the past, acute disseminated encephalomyelitis was associated with specific vaccinations that were produced in neural tissue culture, such as the Semple form of the rabies vaccine and the Japanese B encephalitis vaccine. These cases have become less frequent as recombinant protein vaccines have replaced those cultured from neural tissue (61). Several studies have described rare occurrences of CNS immune-related events about 2 weeks after SARS-CoV-2 vaccination, with acute disseminated encephalomyelitis being one of the common phenotypes (22; 48; 67).
Though the pathogenesis of acute disseminated encephalomyelitis has not been fully elucidated, existing evidence suggests that acute disseminated encephalomyelitis results from an autoimmune response toward myelin-derived antigens. Much of the current thinking regarding the pathogenesis of acute disseminated encephalomyelitis comes from study of the animal model of experimental autoimmune encephalomyelitis, as many features of the induced murine model are notable in human acute disseminated encephalomyelitis. Experimental autoimmune encephalomyelitis is an acute encephalomyelitis that has been induced in a variety of species with introduction of myelin proteins or myelin-derived peptides. Although specific mouse genetic strains can develop a relapsing form of experimental autoimmune encephalomyelitis, most models are characterized by a monophasic illness associated with diffuse CNS demyelination.
Using this animal model, it has been hypothesized that both primary and secondary autoimmune responses contribute to CNS inflammation and subsequent demyelination in acute disseminated encephalomyelitis. The two most widely accepted possible pathogenic mechanisms for acute disseminated encephalomyelitis are molecular mimicry and self-sensitization.
The hypothesis of molecular mimicry is based on the idea that antigenic epitopes are shared between pathogens or vaccines and host myelin antigens. These antigens from pathogens or vaccines subsequently activate myelin-reactive lymphocytes, which can then migrate into the CNS and attack myelin. Many myelin peptides such as myelin basic protein and proteolipid protein have shown similarity to viral sequences and can elicit cross-reactive T-cell responses.
The hypothesis of self-sensitization suggests that direct infection with a neurotropic pathogen results in the release of myelin peptides and a secondary inflammatory response. In the setting of this diffuse inflammation, there is breakdown of the blood-brain barrier, and myelin-derived autoantigens are released into peripheral circulation where they are exposed to naive lymphocytes. These sensitized T-cells may then migrate into the CNS and attack host myelin, causing demyelination in the CNS.
The role of autoantibodies to specific myelin proteins in the pathogenesis of acute disseminated encephalomyelitis and other demyelinating diseases is an area of active research. Multiple studies have shown that myelin oligodendrocyte glycoprotein (MOG) antibodies are found in at least one third of children with acquired demyelinating syndromes. In one study, MOG antibodies were present in 64% of patients with acute disseminated encephalomyelitis, and greater than 95% of those with relapsing acute disseminated encephalomyelitis (ie, multiphasic acute disseminated encephalomyelitis, acute disseminated encephalomyelitis followed by optic neuritis) (21). In this study, about half of the children with MOG antibodies relapsed (21). Another study has shown MOG antibodies to be present in about 57% of children with acute disseminated encephalomyelitis (26). In this study, a high MOG antibody titer was associated with a relapsing non-multiple sclerosis course.
There are no clinical, laboratory, or radiological delineators between MOG-positive and MOG-negative acute disseminated encephalomyelitis at presentation (19). Therefore, given the strong association of MOG antibodies with both monophasic and relapsing acute disseminated encephalomyelitis, we recommend that all children with a clinical suspicion for acute disseminated encephalomyelitis undergo serum MOG antibody testing with a cell-based assay, and that those who are positive undergo serial evaluation to determine whether antibodies are persistent over time. CSF MOG antibody testing is typically not required as MOG-IgG is produced mostly extrathecally, resulting in lower CSF than serum titers (29). In a study assessing the clinical significance of MOG antibodies restricted to CSF in children with neuroinflammatory disorders, 109 of 760 patients (14%) tested positive for MOG antibodies in either serum or CSF; of these, 63 (58%) were positive in both serum and CSF, 37 (34%) only in serum, and 9 (8%) only in CSF (52). This small subset of patients with MOG antibodies restricted to CSF were more likely to be older, have CSF oligoclonal bands, and be diagnosed with multiple sclerosis. Another study assessing MOG antibodies in CSF found that MOG antibodies were detected in the CSF of five (1.8%) out of 268 patients, and all five patients were also positive for MOG in serum (14).
Although the presence of MOG antibodies at presentation are predictive against a subsequent multiple sclerosis disease course (23; 31), a single positive MOG result does not appear sufficient to predict relapsing non-multiple sclerosis clinical phenotypes. One study has suggested, however, that relapse may be more likely in patients with persistent MOG antibodies after acute disseminated encephalomyelitis, defined as those who remained seropositive at a time point at least 3 months after initial presentation (38). Specifically, 15 of 17 patients with persistent MOG seropositivity after acute disseminated encephalomyelitis experienced a relapse, compared to one of eight patients with transient seropositivity and 8 of 24 that were seronegative for MOG (38).
Importantly, demographics and initial clinical features of children with acute disseminated encephalomyelitis who are found to be seropositive for MOG antibodies are indistinguishable from those who are seronegative (12). Multiphasic disseminated encephalomyelitis, a relatively rare clinical disorder, is strongly associated with MOG antibodies (11). By definition, these patients experience at least two discrete episodes of acute disseminated encephalomyelitis.
It is important to emphasize that the spectrum of pediatric MOG antibody-associated syndromes is wider than previously reported and includes encephalitis different from acute disseminated encephalomyelitis. In a prospective study of 239 children with demyelinating syndromes and 296 with encephalitis other than acute disseminated encephalomyelitis, 116 had MOG antibodies. The presenting syndromes in these 116 patients included acute disseminated encephalomyelitis (46 [68%]), encephalitis other than acute disseminated encephalomyelitis (22 [19%]), optic neuritis (20 [17%]), myelitis (13 [11%]), neuromyelitis optica spectrum disorders (6 [5%]), and other disorders (9 [8%]). Children with anti-MOG encephalitis different from acute disseminated encephalomyelitis had a worse clinical outcome. In children with MOG antibodies and acute disseminated encephalomyelitis 13% had a modified Rankin score of at least 2 compared to 36% of children with anti-MOG encephalitis who did not fulfill criteria of acute disseminated encephalomyelitis (04).
In a study analyzing the serum of 15 patients with acute disseminated encephalomyelitis and 26 patients with multiple sclerosis, distinct profiles of autoantibody reactivity to myelin peptides were found in patients with each disease. Specifically, the serum of patients with acute disseminated encephalomyelitis was characterized by IgG autoantibodies targeting myelin basic protein and myelin-associated oligodendrocyte basic protein, whereas the serum of patients with multiple sclerosis was characterized by autoantibodies of the IgM subtype targeting myelin peptides, including proteolipid protein, myelin-associated oligodendrocyte basic protein, and oligodendrocyte-specific protein (65). The finding that IgG autoantibodies, which are class-switched, are predominant in acute disseminated encephalomyelitis supports the notion that acute disseminated encephalomyelitis is a postinfectious process where the immune response is primed prior to the onset of demyelination.
Other autoantibodies, including N-methyl-D-aspartate receptor, glycine receptor, and voltage-gated potassium channel complex antibodies, have been found in some patients with acute disseminated encephalomyelitis although not necessarily at the time of clinical manifestations of acute disseminated encephalomyelitis (24). These results have to be taken with caution. The antibodies when detected only in serum may represent a false positive result. In addition, voltage-gated potassium channel complex antibodies without specificity for LGI1 or CASPR2 are not considered biomarkers of autoimmunity (36).
Perivenous inflammatory infiltrates of T-cells and macrophages associated with perivenular demyelination is the pathologic hallmark of acute disseminated encephalomyelitis, which differs from the more confluent demyelination that is pathologically seen in patients with multiple sclerosis (69). Lesions in acute disseminated encephalomyelitis predominantly involve white matter, though deep gray structures and cortex can also be involved and are typically of similar histologic age (61).
Epidemiology
Acute disseminated encephalomyelitis is primarily a pediatric disease, with the mean age of clinical presentation ranging from 5 to 8 years (27; 03; 61). Although acute disseminated encephalomyelitis can occur at any time of the year, it has been reported to be more common in the winter and spring in temperate climates (39). Incidence rates vary in different cohorts and range from 0.07 to 0.64 per 100,000, though different inclusion criteria and definitions of acute disseminated encephalomyelitis were used in each study (39; 54; 08; 62). In terms of gender predilection, a male predominance has been described in few pediatric cohorts (49; 59; 08).
Prevention
There is currently no evidence or accepted strategy for primary prevention of acute disseminated encephalomyelitis.
Differential diagnosis
Children and adults with acute disseminated encephalomyelitis are acutely ill, sometimes with fever, and, by definition, have altered consciousness. As such, the first priority is to exclude acute CNS infection. CSF analysis and prompt administration of antimicrobial therapy, including acyclovir, is essential until CNS infection is excluded. As the diagnosis of acute disseminated encephalomyelitis is based solely on clinical history and radiographic studies, a number of other inflammatory and infectious diseases should be considered in the differential before a definitive diagnosis is made (Table 1). Although the thalamus is often involved in acute disseminated encephalomyelitis, it can also be involved with deep cerebral vein thrombosis and metabolic disease, which are two entities important to consider in the differential in the proper clinical context. Fulminant cases of acute hemorrhagic leukoencephalitis may mimic acute herpes encephalitis, acute bacterial meningitis, or venous sinus thrombosis. Large tumefactive lesions on MRI may suggest alternate diagnoses such as Marburg variant of multiple sclerosis, tumor, abscess, or CNS vasculitis.
Table 4. Differential Diagnosis of Acute Disseminated Encephalomyelitis
|
Infectious | |
|
• Viral encephalitis (herpes simplex, enterovirus, Mycoplasma pneumoniae) | |
|
Vascular | |
|
• Isolated small vessel CNS vasculitis | |
|
Metabolic | |
|
• Mitochondrial disease | |
|
Inflammatory | |
|
• Multiple sclerosis | |
|
Neoplastic | |
|
• Primary CNS lymphoma | |
|
Miscellaneous | |
|
• Posterior reversible leukoencephalopathy | |
Though differentiating an initial attack of multiple sclerosis from acute disseminated encephalomyelitis may be difficult at the time of the first incident attack, some epidemiologic, clinical, and radiographic features may help to distinguish a first attack of multiple sclerosis from monophasic acute disseminated encephalomyelitis (Table 2). Additionally, as neuromyelitis optica spectrum disorder and MOG antibody-associated disease can initially present with an acute disseminated encephalomyelitis-like event, they should also be considered in the differential for acute disseminated encephalomyelitis.
Table 5. Characteristic Features of Acute Disseminated Encephalomyelitis and Multiple Sclerosis
|
Acute disseminated encephalomyelitis |
Multiple sclerosis | |
|
Demographic |
Common in children and young adults; slight male predominance in a few pediatric cohorts |
Common in adolescents and adults; female predominance |
|
Season |
More common in winter and spring |
No seasonal variation |
|
Precipitating event |
Frequent report of preceding infection |
No clear association |
|
Course |
Typically monophasic |
Relapsing or progressive (primary progressive multiple sclerosis is exceptionally rare in children) |
|
Clinical features |
Acute encephalopathy (behavioral change, altered consciousness), polyfocal neurologic symptoms, seizures, fever, headache |
Encephalopathy and seizures are rare |
|
Oligoclonal bands |
Rare; generally transient if present |
Common (> 95% when evaluated in an experienced laboratory and persistent) |
|
Brain MRI |
Lesions are large, confluent, and multifocal with ill-defined margins |
Lesions have “plaque-like” well-defined margins |
|
Visible lesions in deep gray matter (thalamus and basal ganglia) are frequently noted |
Periaqueductal, corpus callosum, and periventricular white matter often involved | |
|
T1-hypointense lesions rare |
T1-hypointense lesions commonly present at onset | |
|
Follow-up MRI |
Complete or partial resolution of lesions with no new lesions |
New T2-hyperintense and T1-hypointense lesions appear |
|
Outcome |
Often good with minimal residual dysfunction |
Risk of physical disability increases with increasing disease duration |
|
| ||
Diagnostic workup
Investigations when evaluating cases of possible acute disseminated encephalomyelitis are prioritized to first exclude active CNS infection and to evaluate recent viral exposures. CSF analysis (cell count, protein, glucose) should be completed. A mild to moderate CSF lymphocytic pleocytosis is often present (40% to 85% of cases). In severe cases and those with a hemorrhagic component, a pleocytosis of greater than 1000 per mm3, a polymorphonuclear predominance, and red blood cells in the CSF can be seen. CSF protein is elevated in about one half of cases, but levels above 100 mg/dL are rare. Oligoclonal bands are typically negative. This is in contrast to multiple sclerosis, where intrathecal oligoclonal bands are frequently present and persist over time.
Four radiographic patterns of cerebral involvement have been described in acute disseminated encephalomyelitis. These patterns include acute disseminated encephalomyelitis with (1) small lesions (less than 5 mm), (2) large confluent lesions with associated edema and mass effect, (3) additional symmetric bithalamic involvement, and (4) acute hemorrhagic encephalomyelitis (59). Meningeal enhancement is uncommon in acute disseminated encephalomyelitis (though can be seen in some cases of MOGAD), as is the presence of complete ring-enhanced lesions and lesions confined to the corpus callosum (40; 60). Lesions are commonly visible in the thalamus and basal ganglia in acute disseminated encephalomyelitis.
Of note, cases where imaging reveals only small lesions, well-demarcated lesions, or involvement of just one anatomical area are less likely to be MOG-Ab positive (12).
Cerebral MRI abnormalities in children with neuromyelitis optica spectrum disorder can sometimes mimic those seen in cases of acute disseminated encephalomyelitis (41). For example, large confluent lesions affecting the brainstem, hypothalamus, juxtacortical, and periventricular areas have been described in pediatric patients presenting with an acute disseminated encephalomyelitis—like attack who ultimately meet criteria for neuromyelitis optica spectrum disorder (09; 41).
The spine can be affected in up to 28% of patients with acute disseminated encephalomyelitis, and lesions can be longitudinally extensive (49; 59).
In these cases, it is important to also consider the diagnosis of neuromyelitis optica spectrum disorder and MOG antibody-associated disease. Spinal cord imaging features that may be more suggestive of MOG antibody-associated disease include grey matter involvement and conus lesions (20). Spinal cord lesions in multiple sclerosis are typically more focal (45; 17).
Management
Drug treatment. To date, there have been no formal treatment trials for acute disseminated encephalomyelitis, and standard of care is based on observational data and expert consensus (42). Initial treatment of acute disseminated encephalomyelitis involves supportive care. Depending on the clinical situation, antibiotics and antivirals should be started empirically until an infectious etiology has been excluded. When the diagnosis of acute disseminated encephalomyelitis has been confirmed, treatment with corticosteroids should be initiated (methylprednisolone at a dose of 30 mg/kg/day up to 1 gram/day) intravenously for 3 to 5 days. If symptoms resolve, subsequent treatment with oral prednisone is not required. For children with improvement, but still ongoing deficits, a prednisone taper can be used (dose starting at 2 mg/kg/day, with a max of 60 mg/day, tapering over 10 to 14 days) (27; 55).
For patients with acute disseminated encephalomyelitis who fail to demonstrate clinical improvement by the third to fifth day of corticosteroid treatment, or children with life-threatening demyelination at onset, plasma exchange should be considered (16; 55).
Intravenous immunoglobulin has been reported to be effective in some children with acute disseminated encephalomyelitis who do not respond fully to corticosteroids, or in some patients who seem to experience recurrence of neurologic deficits on corticosteroid withdrawal (60; 42). Maintenance monthly intravenous immunoglobulin is typically given to those children who are ultimately diagnosed with MOG antibody-associated disease if they should relapse after their initial attack of acute disseminated encephalomyelitis (25). A retrospective cohort study conducted on patients with relapsing MOGAD showed the annualized relapse rate of those on intravenous immunoglobulin to be 0.13 (95% CI: 0.06–0.27) and the relapse-freedom probability after at least 6 months of therapy to be 72%, which was better compared to pre-treatment, prednisone, mycophenolate mofetil, and B-cell depleting therapies (13).
Some children with acute disseminated encephalomyelitis experience fulminant, life-threatening cerebral edema refractory to conventional medical management. In these cases, decompressive craniectomy may lead to rapid improvement. The most severe form of acute disseminated encephalomyelitis is acute hemorrhagic leukoencephalitis and is thought to be rapidly fatal if not treated promptly. Survival has been reported with combination treatment using corticosteroids, plasmapheresis, and decompressive craniectomy if needed. For cases of life-threatening severe acute CNS demyelination and malignant cerebral edema secondary to MOGAD, tocilizumab been used to successfully mitigate brain edema and improve outcomes (43).
Treatments on the horizon. There are no additional acute or preventative treatments available for acute disseminated encephalomyelitis on the horizon at the current time.
Outcomes
The outcome of monophasic acute disseminated encephalomyelitis is generally favorable as most patients recover without sequelae. Treatment with methylprednisolone is generally well tolerated though providers should be aware of potential side effects associated with high-dose corticosteroids, including hyperglycemia, hypertension, and mood lability. Prolonged use of steroids is not indicated for acute disseminated encephalomyelitis.
Special considerations
Pregnancy
Although there are case reports of acute disseminated encephalomyelitis in pregnant women, there is no known increase in ADEM in the context of pregnancy. Risks and benefits of treatment during pregnancy must be considered on an individual basis. Although immunomodulatory treatment may be indicated to prevent additional morbidity, there may be associated risks with therapies during pregnancy.
Anesthesia
As patients with acute disseminated encephalomyelitis are encephalopathic, use of anesthetic medications should be managed by trained anesthesiologists or intensive care physicians when required. Patients should be monitored closely while receiving anesthesia and in the period after the medication has been administered.
Media
References
- 01
- Alper G. Acute disseminated encephalomyelitis. J Child Neurol 2012;27(11):1408-25. PMID 22914374
- 02
- Alper G, Schor NF. Toward the definition of acute disseminated encephalitis of childhood. Curr Opin Pediatr 2004;16(6):637-40. PMID 15548925
- 03
- Anlar B, Basaran C, Kose G, et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003;34(4):194-9. PMID 12973660
- 04
- Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020 Mar;19(3):234-46. PMID 32057303
- 05
- Aubert-Broche B, Weier K, Longoni G, et al. Monophasic demyelination reduced brain growth in children. Neurology 2017;88(18):1744-50. PMID 28381515
- 06
- Banwell B, Bar-Or A, Arnol DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011;10(5):436-45.** PMID 21459044
- 07
- Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023;22(3):268-82.** PMID 36706773
- 08
- Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009;72(3):232-9. PMID 19153370
- 09
- Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008;70(5):344-52. PMID 18094334
- 10
- Bartels F, Baumgartner B, Aigner A, et al. Impaired brain growth in myelin oligodendrocyte glycoprotein antibody-associated acute disseminated encephalomyelitis. Neurol Neuroimmunol Neuroinflamm 2023;10(2):e200066. PMID 36754833
- 11
- Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016;22(14):1821-9.** PMID 26869530
- 12
- Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86(3):265-72.** PMID 25121570
- 13
- Bilodeau PA, Vishnevetsky A, Molazadeh N, et al. Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler 2024;30(3):357-68. PMID 38314479
- 14
- Burton JM, Youn S, Al-Ani A, Costello F. Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid. J Neurol 2024;271(5):2662-71. PMID 38366070
- 15
- Chen LW, Cheng JF, Chang TM, et al. Prognostic factors for functional recovery in children with moderate to severe acute disseminated encephalomyelitis. Multiple Sclerosis and Related Disorders 2022;66:104056. PMID 35878513
- 16
- Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76(3):294-300. PMID 21242498
- 17
- Dale RC, Branson JA. Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis. Arch Dis Child 2005;90(6):636-9. PMID 15908633
- 18
- de Seze J, Debouverie M, Zephir H, et al. Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol 2007;64(10):1426-32. PMID 17923626
- 19
- Dong X, Jiang Y, Yuan P, et al. Clinical, radiological, therapeutic and prognostic differences between MOG-seropositive and MOG-seronegative pediatric acute disseminated encephalomyelitis patients: a retrospective cohort study. Front Neurosci 2023;17:1128422. PMID 37274199
- 20
- Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019;76:301-9. PMID 30575890
- 21
- Duignan S, Wright S, Rossor T, et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 2018;60(9):958-62. PMID 29468668
- 22
- Faksova K, Walsh D, Jiang Y, et al. COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine 2024;42(9):2200-11. PMID 38350768
- 23
- Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015;2(2):e81. PMID 25798445
- 24
- Hacohen Y, Absoud M, Woodhall M, et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry 2014;85(4):456-61. PMID 24133290
- 25
- Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol 2019 22;21(1):2. PMID 30671648
- 26
- Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017;89(9):900-8. PMID 28768844
- 27
- Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001;56(10):1308-12. PMID 11376179
- 28
- Jacobs RK, Anderson VA, Neale JL, Shield LK, Kornberg AJ. Neuropsychological outcome after acute disseminated encephalomyelitis: impact of age at illness onset. Pediatr Neurol 2004;31(3):191-7. PMID 15351018
- 29
- Jarius S, Paul F, Atkas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15(1):134. PMID 29724224
- 30
- Johnson RT. The pathogenesis of acute viral encephalitis and postinfectious encephalomyelitis. J Infect Dis 1987;155(3):359-64. PMID 3027198
- 31
- Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies please against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015;21(12):1513-20. PMID 25662345
- 32
- Ketelslegers IA, Visser IE, Neuteboom RF, Boon M, Catsman-Berrevoets CE, Hintzen RQ. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler 2011;17(4):441-8. PMID 21148017
- 33
- Krupp LB, Banwell B, Tenembaum S; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68(16 Suppl 2):S7-12.** PMID 17438241
- 34
- Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revision to the 2007 definitions. Mult Scler 2013;19(10):1261-7. PMID 23572237
- 35
- Kuni BJ, Banwell BL, Till C. Cognitive and behavioral outcomes in individuals with a history of acute disseminated encephalomyelitis (ADEM). Dev Neuropsychol 2012;37(8):682-96. PMID 23145566
- 36
- Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry 2017;88(4):353-61. PMID 28115470
- 37
- Longoni G, Brown RA, MomayyezSiahkal P, et al. White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain 2017;140(5):1300-15. PMID 28334875
- 38
- Lopez-Chiriboga AS, Majed M, Freyer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 2018;75(11):1355-63. PMID 30014148
- 39
- Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004;23(8):756-64. PMID 15295226
- 40
- Lim KE, Hsu YY, Hsu WC, Chan CY. Multiple complete ring-shaped enhanced MRI lesions in acute disseminated encephalomyelitis. Clin Imaging 2003;27(4):281-4. PMID 12823926
- 41
- Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008;122(5):1039-47. PMID 18838462
- 42
- Massa S, Fracchiolla A, Neglia C, Argentiero A, Esposito S. Update on acute disseminated encephalomyelitis in children and adolescents. Children (Basel) 2021;8(4):280. PMID 33917395
- 43
- McLendon LA, Gambrah-Lyles C, Viaene A, et al. Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease. Neurol Neuroimmunol Neuroinflamm 2023;10(6):e200150. PMID 37582615
- 44
- McLendon LA, Rao CK, Da Hora CC, Islamovic F, Galan FN. Post-COVID-19 acute disseminated encephalomyelitis in a 17-month-old. Pediatrics 2021;147(6):e2020049678. PMID 33762311
- 45
- Mikaeloff Y, Adamsbaum C, Husson B, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004;127(Pt 9):1942-7. PMID 15289266
- 46
- Mikaeloff Y, Caridade G, Husson B, Suissa S, Tardieu M; Neuropediatric KIDSEP Study Group of the French Neuropediatric Society. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007;11(2):90-5. PMID 17188007
- 47
- Miller HG, Stanton JB, Gibbons JL. Acute disseminated encephalomyelitis and related syndromes. Br Med J 1957;1(5020):668-72. PMID 13404268
- 48
- Morgan HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, Buttery JP. Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - a self-controlled case series analysis. Vaccine 2024;42(9):2212-9. PMID 38350771
- 49
- Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002;110(2 Pt 1):e21. PMID 12165620
- 50
- Niemeyer B, Niemeyer R, Borges R, Marchiori E. Acute disseminated encephalomyelitis following Zika virus infection. Eur Neurol 2017;77(1-2):45-6. PMID 27894121
- 51
- Nishiyama M, Nagase H, Tomikoka K, et al. Clinical time course of pediatric acute disseminated encephalomyelitis. Brain Dev 2019;41(6):531-7. PMID 30833092
- 52
- Olive-Cirera G, Bruijstens AL, Fonseca EG, et al. MOG antibodies restricted to CSF in children with inflammatory CNS disorders. Neurology 2024;102(7):e209199. PMID 38447115
- 53
- Pedrosa DA, de Paula Oliveira LKL, Bertanha R, Júnior EA, Fernandes GBP, Thomaz RB. Acute disseminated encephalomyelitis following Saint Louis encephalitis virus infection. Neurol Sci 2024;45(3):1263-6. PMID 38177968
- 54
- Pohl D, Hennemuth I, von Kries R, Hanefeld F. Pediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr 2007;166(5):405-12. PMID 17219129
- 55
- Pohl D, Tenembaum S. Treatment of acute disseminated encephalomyelitis. Curr Treat Options Neurol 2012;14(3):264-75. PMID 22476745
- 56
- Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89(2):127-37.** PMID 29142145
- 57
- Suppiej A, Cainelli E, Casara G, Cappellari A, Nosadini M, Sartori S. Long-term neurocognitive outcome and quality of life in pediatric acute disseminated encephalomyelitis. Pediatr Neurol 2014;50(4):363-7. PMID 24630282
- 58
- Teixeira AAR, Ferreira LF, Pires Neto RDJ. Acute disseminated encephalomyelitis after Chikungunya infection. JAMA Neurol 2019;76(5):619. PMID 30830174
- 59
- Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002;59(8):1224-31. PMID 12391351
- 60
- Tenembaum S, Chitnis T, Ness J, Hahn JS; International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007;68(16 Suppl 2):S23-36.** PMID 17438235
- 61
- Tenembaum SN. Acute disseminated encephalomyelitis. Handb Clin Neurol 2013;112:1253-62. PMID 23622336
- 62
- Torisu H, Kira R, Ishizaki Y, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010;32(6):454-62. PMID 19942388
- 63
- Toussaint-Duyster LC, Wong YYM, Van der Cammen-van Zijp MH, et al. Fatigue and physical function in children with multiple sclerosis and acute disseminated encephalomyelitis. Mult Scler 2018;24(7):982-90. PMID 28445083
- 64
- van Bogaert L. Post-infectious encephalomyelitis and multiple sclerosis; the significance of perivenous encephalomyelitis. J Neuropathol Exp Neurol 1950;9(3):219-49. PMID 15437201
- 65
- Van Haren K, Tomooka BH, Kidd BA, et al. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler 2013;19(13):1726-33. PMID 23612879
- 66
- Verhey LH, Branson HM, Shroff MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011;10(12):1065-73. PMID 22067635
- 67
- Vogrig A, Tartaglia S, Dentoni M, et al. Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study. Front Immunol 2024;15:1344184. PMID 38375477
- 68
- Weier K, Fonov V, Aubert-Broche B, Arnold DL, Banwell B, Collins DL. Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease. Mult Scler 2016;22(10):1266-78. PMID 26552732
- 69
- Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010;133(Pt 2):333-48. PMID 20129932
- 70
- Zelada-Rios L, Pacheco-Barrios K, Galecio-Castillo M, et al. Acute disseminated encephalomyelitis and COVID-19: a systematic synthesis of worldwide cases. J Neuroimmunol 2021;359:577674. PMID 34371208
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Authors
-
Sona Narula MD
Dr. Narula of Children's Hospital of Philadelphia received research support from Alexion Pharmaceuticals as principal investigator.
See Profile -
Amaar Marefi MD
Dr. Marefi of Children's Hospital of Philadelphia has no relevant financial relationships to disclose.
See Profile
Editor
-
Francesc Graus MD PhD
Dr. Graus, Emeritus Professor, Laboratory Clinical and Experimental Neuroimmunology, Institut D’Investigacions Biomédiques August Pi I Sunyer, Hospital Clinic, Spain, has no relevant financial relationships to disclose.
See Profile
Former Authors
- David H Mattson MD PhD
- Nirjal Nikhar MD
- Ravindra Kumar Garg DM FRCP
- Brenda Banwell MD
Patient Profile
- Age range of presentation
-
- 1 month to 65+ years
- Sex preponderance
-
- male > female in some cohorts
- Heredity
-
- none
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Acute disseminated encephalitis and encephalomyelitis: G04.0
- Acute disseminated encephalitis and encephalomyelitis, unspecified: G04.00
- Postinfectious acute disseminated encephalitis and encephalomyelitis: G04.01
- Postimmunization acute disseminated encephalitis, myelitis, and encephalomyelitis: G04: 02
- ICD-11
-
- Acute disseminated encephalomyelitis: 8A42
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuroimmunology
Anti-IgLON5 disease
Oct. 10, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Neuroimmunology
Progressive encephalomyelitis with rigidity and myoclonus and glycine receptor antibodies
Oct. 03, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Giant cell arteritis
Sep. 25, 2024
-
Neuroimmunology
Chronic inflammatory demyelinating polyradiculoneuropathy
Sep. 07, 2024
-
Neuroimmunology
Autoimmune autonomic neuropathy
Aug. 31, 2024
-
Neuroimmunology
HTLV-1 associated myelopathy
Aug. 29, 2024